NEW YORK--(BUSINESS WIRE)--Nucleus Genomics, the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

纽约--（商业新闻短讯）--下一代基因检测和分析公司Nucleus Genomics今天宣布推出其DNA分析产品，为每个人带来个性化医疗的好处。

DNA and health are inextricably linked, but profound insights into how DNA can shape health are missing from healthcare. Customers who’ve previously done microarray genetic testing with older testing companies can upload their DNA data onto Nucleus’ platform to receive greater insights into their genetic risk for diseases like type 2 diabetes, breast cancer, and many more.

DNA与健康有着不可分割的联系，但医疗保健却缺少对DNA如何塑造健康的深刻见解。以前曾与较老的检测公司进行过微阵列基因检测的客户可以将其DNA数据上传到Nucleus的平台上，以更深入地了解他们患2型糖尿病、乳腺癌等疾病的遗传风险。

Nucleus further personalizes these risk assessments by integrating personal and lifestyle factors into their analysis — such as age, cholesterol levels, blood pressure, and BMI..

Nucleus通过将个人和生活方式因素纳入其分析中（例如年龄，胆固醇水平，血压和BMI），进一步个性化了这些风险评估。。

Nucleus will also offer pre-orders for its premium clinical-grade whole-genome sequencing (WGS) service, in which a customer’s entire set of DNA will be read and analyzed. These more comprehensive WGS results will start to become available in the summer.

Nucleus还将为其优质临床级全基因组测序（WGS）服务提供预订，其中将读取和分析客户的整套DNA。这些更全面的WGS结果将在夏季开始提供。

For a yearly membership fee of $39, members will receive access to new features on Nucleus’ platform, as well as new disease reports and, eventually, reports for traits like height and muscle strength. The 30x WGS kit costs $399.

会员每年只需缴纳39美元的会费，就可以访问Nucleus平台上的新功能，以及新的疾病报告，并最终获得身高和肌肉力量等特征的报告。30倍WGS套件售价399美元。

“Nucleus is combining the power of whole-genome sequencing with our innovative genomic analyses — ushering in a new era of personalized medicine to the public,” says founder and CEO Kian Sadeghi. 'DNA insights will become a commonplace tool that everyone uses to make important decisions about their health and lifestyle.'.

“Nucleus将全基因组测序的力量与我们创新的基因组分析相结合，开创了面向公众的个性化医疗的新时代，”创始人兼首席执行官KianSadeghi说DNA洞察将成为每个人用来对自己的健康和生活方式做出重要决定的常用工具。”。

Nucleus is proud to sequence all customer samples in the U.S. on Illumina’s NovaSeq X Plus, the sequencing company’s newest and most innovative high-throughput sequencing instrument. Working with Illumina, Nucleus is leveraging this latest sequencing technology to make WGS broadly accessible to power personalized healthcare..

Nucleus很自豪能在Illumina的NovaSeq X Plus上对美国所有客户样品进行测序，这是测序公司最新和最具创新性的高通量测序仪器。Nucleus与Illumina合作，利用这项最新的测序技术，使WGS广泛用于个性化医疗保健。。

Nucleus has also been awarded CLIA certification and CAP accreditation for its WGS informatics laboratory in North Carolina. This ensures customer whole-genome sequencing results are always of the highest, clinical-grade quality.

Nucleus位于北卡罗来纳州的WGS信息学实验室也获得了CLIA认证和CAP认证。这确保了客户的全基因组测序结果始终具有最高的临床级质量。

The company also offers its WGS members access to SteadyMD, an independent network of doctors and board-certified genetic counselors, who can help customers better understand the implications of their WGS results, for themselves and their families.

该公司还为其WGS成员提供了SteadyMD的访问权限，SteadyMD是一个由医生和董事会认证的遗传咨询师组成的独立网络，可以帮助客户更好地了解其WGS结果对自己和家人的影响。

Personalized insights, always meaningful

个性化见解，始终有意义

The company — which raised a total of $18 million in seed funding in 2022 from venture capital firms such as Alexis Ohanian's Seven Seven Six and Peter Thiel’s Founders Fund – aims to use the power of genomics to help people live longer and healthier by providing insights into the genetics underpinning their health and well-being..

2022年，该公司从亚历克西斯·奥哈尼安的七七六和彼得·泰尔的创始人基金等风险投资公司共筹集了1800万美元的种子资金，旨在利用基因组学的力量，通过深入了解支撑人们健康和福祉的基因，帮助人们活得更长、更健康。。

Nucleus will provide polygenic risk scores (PRS), an innovative analysis that calculates the combined impact of common DNA variants on a person’s disease risks and trait dispositions. The analysis also integrates an individual’s environmental and lifestyle information for a more comprehensive picture of their overall or absolute risk for complex, common diseases.

Nucleus将提供多基因风险评分（PRS），这是一项创新分析，可计算常见DNA变异对人的疾病风险和特质倾向的综合影响。该分析还整合了个人的环境和生活方式信息，以更全面地了解他们患复杂常见疾病的总体或绝对风险。

As people change over their lifetimes and as new scientific discoveries are made, Nucleus members’ disease risk scores will automatically update — evolving with them to stay relevant and meaningful..

随着人们一生的变化和新的科学发现的产生，核心成员的疾病风险评分将自动更新-随着他们的发展而不断变化，以保持相关性和意义。。

By adding WGS to the analysis, Nucleus can also identify rare, high-impact variants. These variants exist across both common and rare disorders, like those found in the BRCA1 and BRCA2 genes that significantly increase the risk for breast and other cancers.

通过将WGS添加到分析中，Nucleus还可以识别罕见的高影响变体。这些变异存在于常见和罕见疾病中，例如在BRCA1和BRCA2基因中发现的变异，这些变异会显着增加患乳腺癌和其他癌症的风险。

“Nucleus is the all-in-one genetic test,” says Sadeghi. “The promise of the Human Genome Project has finally arrived.”

Sadeghi说：“Nucleus是一种综合性的基因检测。”。“人类基因组计划的希望终于实现了。”

About Nucleus Genomics

关于Nucleus Genomics

Nucleus is redefining next-generation genetic testing and analysis. By combining polygenic scores with traditional rare variant DNA analysis, the company provides comprehensive assessments of genetic disposition across a myriad of diseases and traits. Nucleus’ mission is to empower people to take agency over their health so no one dies from preventable disease — that’s why the company is building a platform based on cutting-edge science, where everyone has their genome at their fingertips, complete clarity on their risks, and are empowered by personalized health measures.

Nucleus正在重新定义下一代基因检测和分析。通过将多基因评分与传统的稀有变异DNA分析相结合，该公司可以对多种疾病和性状的遗传倾向进行全面评估。Nucleus的使命是让人们能够接管自己的健康，这样就不会有人死于可预防的疾病——这就是为什么该公司正在建立一个基于尖端科学的平台，在这个平台上，每个人都有自己的基因组，完全清楚自己的风险，并通过个性化的健康措施获得授权。

Nucleus is also bridging the gap between people, doctors, and scientists — helping discoveries, therapies, and cures find their way to individuals faster. Learn more at mynucleus.com..

Nucleus还弥合了人们、医生和科学家之间的差距，帮助发现、治疗和治愈更快地找到适合个人的方法。请访问mynucleus.com了解更多信息。。